Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 7.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 269,990 shares of the biotechnology company's stock after buying an additional 17,754 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.42% of Blueprint Medicines worth $23,549,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Torray Investment Partners LLC increased its stake in Blueprint Medicines by 1.1% during the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock worth $1,439,000 after purchasing an additional 186 shares during the period. Franklin Resources Inc. grew its holdings in shares of Blueprint Medicines by 0.7% in the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after purchasing an additional 265 shares in the last quarter. Hillsdale Investment Management Inc. increased its stake in Blueprint Medicines by 0.6% during the 4th quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock worth $4,433,000 after buying an additional 310 shares during the period. Quarry LP acquired a new stake in Blueprint Medicines during the 3rd quarter worth approximately $32,000. Finally, Van ECK Associates Corp boosted its position in Blueprint Medicines by 48.2% in the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company's stock valued at $97,000 after buying an additional 363 shares during the period.

Remove Ads

Analyst Ratings Changes

BPMC has been the subject of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $133.00 target price on shares of Blueprint Medicines in a report on Tuesday. JMP Securities reissued a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. StockNews.com cut shares of Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. boosted their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Finally, Stephens restated an "overweight" rating and issued a $140.00 price objective on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $124.95.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares of the company's stock, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 15,161 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the completion of the sale, the director now owns 152,396 shares of the company's stock, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,608 shares of company stock valued at $3,319,587 in the last ninety days. Insiders own 4.21% of the company's stock.

Blueprint Medicines Stock Performance

Shares of BPMC traded up $0.57 during mid-day trading on Friday, reaching $80.84. 1,646,653 shares of the company's stock were exchanged, compared to its average volume of 763,520. The business's fifty day simple moving average is $90.91 and its 200-day simple moving average is $93.51. Blueprint Medicines Co. has a 52-week low of $73.04 and a 52-week high of $121.90. The stock has a market capitalization of $5.17 billion, a PE ratio of -74.85 and a beta of 0.75. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, equities research analysts expect that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.